Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
John D. Abad; Claudia Wrzensinski; Willem Overwijk; Moniek A. De Witte; Annelies Jorritsma; Cary Hsu; Luca Gattinoni; Cyrille J. Cohen; Chrystal M. Paulos; et al. (Profiled Author: Willem Overwijk)
Journal of Immunotherapy. 2008;31(1):1-6.Abstract
Adoptive cell transfer therapy using tumor-infiltrating lymphocytes for patients with metastatic melanoma has demonstrated significant objective response rates. One major limitation of these current therapies is the frequent inability to isolate tumor-reactive lymphocytes for treatment. Genetic engineering of peripheral blood lymphocytes with retroviral vectors encoding tumor antigen-specific T-cell receptors (TCRs) bypasses this restriction. To evaluate the efficacy of TCR gene therapy, a murine treatment model was developed. A retroviral vector was constructed encoding the pmel-1 TCR genes targeting the B16 melanoma antigen, gp100. Transduction of C57BL/6 lymphocytes resulted in efficient pmel-1 TCR expression. Lymphocytes transduced with this retrovirus specifically recognized gp100-pulsed target cells as measured by interferon-γ secretion assays. Upon transfer into B16 tumor-bearing mice, the genetically engineered lymphocytes significantly slowed tumor development. The effectiveness of tumor treatment was directly correlated with the number of TCR-engineered T cells administered. These results demonstrated that TCR gene therapy targeting a native tumor antigen significantly delayed the growth of established tumors. When C57BL/6 lymphocytes were added to antigen-reactive pmel-1 T cells, a reduction in the ability of pmel-1 T cell to treat B16 melanomas was seen, suggesting that untransduced cells may be deleterious to TCR gene therapy. This model may be a powerful tool for evaluating future TCR gene transfer-based strategies. © 2008 Lippincott Williams & Wilkins, Inc.
PMID: 18157006 PMCID: PMC2235937
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Dennis P.M. Hughes; D. Baskar; F.A. Urban; M.S. Friedman; T.M. Braun; K.T. McDonaghCytotherapy. 2005;7(5):396-407.
Lauren I. Richie Ehrlich; Kouetsu Ogasawara; Jessica A. Hamerman; Rayna Takaki; Alessandra Zingoni; James P. Allison; Lewis L. LanierJournal of Immunology. 2005;174(4):1922-1931.
Willem W. Overwijk; Marc R. Theoret; Steven E. Finkelstein; Deborah R. Surman; Laurina A. De Jong; Florry A. Vyth-Dreese; Trees A. Dellemijn; Paul A. Antony; Paul J. Spiess; Douglas C. Palmer; et al.Journal of Experimental Medicine. 2003;198(4):569-580.
Appears in this Document